HSC-100 is under clinical development by Tacitus Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HSC-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HSC-100 overview
HSC-100 is under development for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma and Hodgkin lymphoma. It is administered through parenteral route. The therapeutic candidate comprises of valproic acid (VPA) expanded allogeneic hematopoietic stem cells (HSCs) expanded from umbilical cord blood (CB).
For a complete picture of HSC-100’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.